TMDX TRANSMEDICS GROUP INC revenue, earnings and financials

For the quarter ended June 30, 2026, TRANSMEDICS GROUP INC reported revenue of $190M (up 20.7% from a year earlier), net income of $14.7M and diluted EPS of $0.41; over the last four quarters revenue was $668M and net income $152M; for the fiscal year ended December 2025 revenue was $605M, up 37.1% on the year before.

TMDX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $605M, gross profit $363M, operating income $109M, net income $190M (margin 31.4%), EPS $4.87
• Fiscal year ended Dec 2024: revenue $442M, gross profit $262M, operating income $37.5M, net income $35.5M (margin 8.0%), EPS $1.01
• Fiscal year ended Dec 2023: revenue $242M, gross profit $154M, operating income −$28.7M, net income −$25.0M (margin -10.3%), EPS −$0.77
• Fiscal year ended Dec 2022: revenue $93.5M, gross profit $65.3M, operating income −$31.4M, net income −$36.2M (margin -38.7%), EPS −$1.23
• Fiscal year ended Dec 2021: revenue $30.3M, gross profit $21.2M, operating income −$39.4M, net income −$44.2M (margin -146.1%), EPS −$1.60

TMDX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $190M (up 20.7% year over year), net income $14.7M, EPS $0.41
• Quarter ended Mar 31, 2026: revenue $174M (up 21.2% year over year), net income $7.32M, EPS $0.20
• Quarter ended Dec 31, 2025 (from the annual report): revenue $161M (up 32.2% year over year), net income $105M, EPS $2.59
• Quarter ended Sep 30, 2025: revenue $144M (up 32.2% year over year), net income $24.3M, EPS $0.66
• Quarter ended Jun 30, 2025: revenue $157M (up 37.7% year over year), net income $34.9M, EPS $0.92
• Quarter ended Mar 31, 2025: revenue $144M (up 48.2% year over year), net income $25.7M, EPS $0.70
• Quarter ended Dec 31, 2024 (from the annual report): revenue $122M (up 49.8% year over year), net income $6.89M, EPS $0.19
• Quarter ended Sep 30, 2024: revenue $109M (up 63.7% year over year), net income $4.22M, EPS $0.12
• Quarter ended Jun 30, 2024: revenue $114M (up 117.9% year over year), net income $12.2M, EPS $0.35
• Quarter ended Mar 31, 2024: revenue $96.9M (up 133.1% year over year), net income $12.2M, EPS $0.35
• Quarter ended Dec 31, 2023 (from the annual report): revenue $81.2M (up 158.7% year over year), net income $4.06M, EPS $0.12
• Quarter ended Sep 30, 2023: revenue $66.4M (up 158.7% year over year), net income −$25.4M, EPS −$0.78
• Quarter ended Jun 30, 2023: revenue $52.5M (up 155.7% year over year), net income −$1.00M, EPS −$0.03
• Quarter ended Mar 31, 2023: revenue $41.6M (up 161.7% year over year), net income −$2.64M, EPS −$0.08
• Quarter ended Dec 31, 2022 (from the annual report): revenue $31.4M (up 224.5% year over year), net income −$6.69M, EPS −$0.19
• Quarter ended Sep 30, 2022: revenue $25.7M (up 378.3% year over year), net income −$7.43M, EPS −$0.25
• Quarter ended Jun 30, 2022: revenue $20.5M (up 151.1% year over year), net income −$11.5M, EPS −$0.41
• Quarter ended Mar 31, 2022: revenue $15.9M (up 125.2% year over year), net income −$10.6M, EPS −$0.38
• Quarter ended Dec 31, 2021 (from the annual report): revenue $9.67M, net income −$12.7M, EPS −$0.45
• Quarter ended Sep 30, 2021: revenue $5.37M, net income −$13.0M, EPS −$0.47

TMDX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $193M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2024: operating cash flow $48.8M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2023: operating cash flow −$13.0M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2022: operating cash flow −$45.8M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2021: operating cash flow −$28.9M, share buybacks n/a, dividends $0.00 per share

TMDX balance sheet

• Jun 30, 2026: cash n/a, total assets $1.46B, total liabilities $946M, shareholders' equity $518M
• Mar 31, 2026: cash n/a, total assets $1.43B, total liabilities $941M, shareholders' equity $494M
• Dec 31, 2025: cash n/a, total assets $1.07B, total liabilities $595M, shareholders' equity $473M
• Sep 30, 2025: cash n/a, total assets $946M, total liabilities $591M, shareholders' equity $355M
• Jun 30, 2025: cash n/a, total assets $891M, total liabilities $572M, shareholders' equity $318M
• Mar 31, 2025: cash n/a, total assets $838M, total liabilities $571M, shareholders' equity $266M
• Dec 31, 2024: cash n/a, total assets $804M, total liabilities $575M, shareholders' equity $229M
• Sep 30, 2024: cash $330M, total assets $786M, total liabilities $576M, shareholders' equity $210M

What is TMDX's revenue?

TRANSMEDICS GROUP INC reported $668M of revenue over its last four quarters, through June 30, 2026.

Is TMDX profitable?

Yes. TRANSMEDICS GROUP INC earned $152M over the last four quarters.

What is TMDX's EPS?

Diluted earnings per share over the last four quarters were $3.86; $0.41 in the latest quarter.

TMDX ownership and insider trades · All stocks